ProSeal™ Bag Spike with Additive Port (423370ST, 423370)

K251340 · Epic Medical Pte. , Ltd. · ONB · May 29, 2025 · General Hospital

Device Facts

• Record ID: K251340
• Device Name: ProSeal™ Bag Spike with Additive Port (423370ST, 423370)
• Applicant: Epic Medical Pte. , Ltd.
• Product Code: ONB · General Hospital
• Decision Date: May 29, 2025
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 880.5440
• Device Class: Class 2

Intended Use

The ProSeal™ CSTD mechanically prohibits environmental contaminants from entering the system and the escape of drug or vapor concentrations from the system, thereby minimizing individual and environmental exposure to drug vapor, aerosols, and spills. The ProSeal™ system also prevents the introduction of microbial contaminations into the drug or fluid path for up to 7 days when used as intended.

Device Story

Adaptor between I.V. bags and ProSeal™ CSTD components; facilitates closed system fluid transfer. Input: I.V. bag connection; generic I.V. spikes. Operation: Uses elastomeric double membrane technology for airtight/leak-proof connections; includes spiking port with TPE stopper. Output: Closed fluid path for drug administration. Used in clinical settings by healthcare professionals. Benefits: Minimizes exposure to hazardous drug vapors/aerosols/spills; prevents microbial ingress for up to 7 days.

Clinical Evidence

No clinical data. Bench testing only. Performance verified via leak integrity, tensile strength, flow rate, protective caps, spike penetration force, vapor containment, and 7-day microbial ingress testing per ISO 8536-4, ISO 22413, and ANSI AAMI CN27 standards. Biocompatibility assessed per ISO 10993 series.

Technological Characteristics

Materials: Polyisoprene (membrane), Polypropylene (spike port), Thermoplastic elastomer (spiking port stopper). Principle: Elastomeric double membrane for airtight/leak-proof connection. Form factor: 3-port access device. Sterilization: Ethylene Oxide (EO) to SAL 10^-6. Shelf-life: 3 years. Single-use.

Indications for Use

Indicated for use by adequately trained healthcare professionals in clinical settings for closed system fluid transfer of parenteral drugs.

Regulatory Classification

Identification

An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.

Special Controls

*Classification.* Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.

Predicate Devices

• ProSeal™ Closed System Bag Access (K241988)

Reference Devices

• ProSeal™ Injector or Injector Plus (K240171)
• ProSeal™ Closed System Administration Set (K230343)
• eZSURE™ Empty Fluid Container (K223674)
• Injection Site w/Extended MLL (K240433)
• K222929
• K151650

Submission Summary (Full Text)

{0}

FDA U.S. FOOD & DRUG ADMINISTRATION

May 29, 2025

Epic Medical Pte. Ltd.
Freddie Lee
CEO/MD
105 Cecil Street #20-04, The Octagon
Singapore, SG 069534
Singapore

Re: K251340
Trade/Device Name: ProSeal™ Bag Spike with Additive Port (423370ST, 423370)
Regulation Number: 21 CFR 880.5440
Regulation Name: Intravascular Administration Set
Regulatory Class: Class II
Product Code: ONB
Dated: April 30, 2025
Received: April 30, 2025

Dear Freddie Lee:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K251340 - Freddie Lee
Page 2

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}

K251340 - Freddie Lee
Page 3

Sincerely,


David Wolloscheck, Ph.D.
Assistant Director
DHT3C: Division of Drug Delivery and
General Hospital Devices, and
Human Factors
OHT3: Office of Gastrorenal, ObGyn,
General Hospital, and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

{3}

FORM FDA 3881 (8/23)
Page 1 of 1
PSC Publishing Services [phone]
EF

| DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use | Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026 See PRA Statement below. |
| --- | --- |
| 510(k) Number (if known) K251340 | |
| Device Name ProSeal™ Bag Spike with Additive Port (423370ST, 423370) | |
| Indications for Use (Describe) The ProSeal™ CSTD mechanically prohibits environmental contaminants from entering the system and the escape of drug or vapor concentrations from the system, thereby minimizing individual and environmental exposure to drug vapor, aerosols, and spills. The ProSeal™ system also prevents the introduction of microbial contaminations into the drug or fluid path for up to 7 days when used as intended. | |
| Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. | |
| This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* | |
| The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail] | |
| "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." | |

{4}

EPIC

# K251340 – 510(k) Summary

## I. Submitter

Epic Medical Pte. Ltd.
105 Cecil Street #20-04,
The Octagon,
Singapore 069534
Phone: [phone]
Contact Person: Mr. Freddie LEE, Chief Executive Officer/ Managing Director
Date Prepared: May 26, 2025
Content and Format: Prepared in accordance with 21 CFR 807.92
Type of Submission: Special

## II. Subject Device

| 510(k) Number: | K251340 |
| --- | --- |
| Trade/ Device Name: | ProSeal™ Bag Spike with Additive Port (423370ST, 423370) |
| Common/ Usual Name: | Closed Antineoplastic and Hazardous Drug Reconstitution and Transfer System |
| Regulation Number: | Set, Administration, Intravascular |
| Regulation Name: | 21 CFR 880.5440 |
| Regulatory Class: | Class: II |
| Product Code: | ONB |

## III. Predicate

| 510(k) Number: | K241988 |
| --- | --- |
| Trade/ Device Name: | ProSeal™ Closed System Bag Access |
| Common/ Usual Name: | Closed Antineoplastic and Hazardous Drug Reconstitution and Transfer System |
| Regulation Number: | Set, Administration, Intravascular |
| Regulation Name: | 21 CFR 880.5440 |
| Regulatory Class: | Class: II |
| Product Code: | ONB |

Page 1 of 7

{5}

EPIC

## IV. Purpose of Submission and Device Description

This special 510(k) Submission is to comply with FDA requirements, ensuring the ProSeal™ Bag Spike with Additive Port (or “and Seal Tab”) is safe and effective for use in closed system fluid transfer applications.

The ProSeal™ Bag Spike with Additive Port (or “and Seal Tab” (simplified ST model no.)) serves as an adaptor between I.V. bags and ProSeal™ CSTD components, facilitating closed system fluid transfer. The spiking port of this device is compatible with generic I.V. spikes. Additionally, the additive port (injection site) allows medication to be added to the bag using the cleared ProSeal™ Injector or Injector Plus (both Syringe Adaptors).

The injection site of the ProSeal™ Bag Spike with Additive Port (or “and Seal Tab”) and all corresponding interface membranes ensure a dry connection during fluid transfer. Utilizing this component and its appropriate ProSeal™ CSTD connecting component reduces the risk of microbial ingress for up to 168 hours (7 days).

## V. Indications for Use Statement

The ProSeal™ CSTD mechanically prohibits environmental contaminants from entering the system and the escape of drug or vapor concentrations from the system, thereby minimizing individual and environmental exposure to drug vapor, aerosols, and spills. The ProSeal™ system also prevents the introduction of microbial contaminations into the drug or fluid path for up to 7 days when used as intended.

## VI. Comparison of Intended Use & Technological Characteristics

The Subject device and the Predicate device share the following characteristics:

### Intended Use comparison

1) Indications for use statements
2) Primary product code and regulation number
3) Intended user population/ intended use environment
4) Intended drug type
5) Prescription use or over-the-counter use

### Technological characteristics comparison

### Equivalencies – Technology & Design

The Subject device and the Predicate device share the following design characteristics, and from the evaluation in the comparison table, there was no substantial difference from the Predicate device identified, that would raise a safety or performance issue/ concern:

1) Connection between component devices within the CSTD system
2) Transfer mechanism (role: to facilitate airtight & leak-proof connections to prevent microbial contamination)
3) Sterile barrier packaging
4) Sterilization process
5) Shelf-life validation
6) Reuse or single-use
7) Labeling specifications

Page 2 of 7

{6}

EPIC

# Comparison of intended use characteristics and the technological characteristics

An overview table summarizing the comparison of the key characteristics between the Subject and the Predicate device is provided hereunder:

Comparison of intended use characteristics and the technological characteristics

| Characteristic compared | Predicate Device (K241988) ProSeal™ Closed System Bag Access | Subject Device (K251340) ProSeal™ Bag Spike with Additive Port | Comment/Discussion |
| --- | --- | --- | --- |
| Intended use and Indications for Use statement | The ProSeal™ CSTD system mechanically prohibits environmental contaminants from entering the system and the escape of drug or vapor concentrations from the system, thereby minimizing individual and environmental exposure to drug vapor, aerosols, and spills. The ProSeal™ system also prevents the introduction of microbial contaminants into the drug or fluid path for up to 7 days when used as intended. | The ProSeal™ CSTD system mechanically prohibits environmental contaminants from entering the system and the escape of drug or vapor concentrations from the system, thereby minimizing individual and environmental exposure to drug vapor, aerosols, and spills. The ProSeal™ system also prevents the introduction of microbial contaminants into the drug or fluid path for up to 7 days when used as intended. | Same |
| Primary product code and regulation number | ONB 21 CFR 880.5440 | ONB 21 CFR 880.5440 | Same |
| Intended user population/ intended use environment | Adequately trained health care professionals/ clinical setting | Adequately trained health care professionals/ clinical setting | Same |
| Intended drug type | Parenteral drugs | Parenteral drugs | Same |
| Prescription use or over-the-counter use | R only | R only | Same |

{7}

EPIC

Comparison of intended use characteristics and the technological characteristics

| Characteristic compared | Predicate Device (K241988) ProSeal™ Closed System Bag Access | Subject Device (K251340) ProSeal™ Bag Spike with Additive Port | Comment/Discussion |
| --- | --- | --- | --- |
| Principles of operation | The infusion bag is connected with the bag access and, in order to create a fluid path connection between the infusion bag and the bag access, they are connected with the matching end of the ProSeal Injector or Injector Plus (K240171). All system components are sealed with self-resealing membranes incorporating elastomeric double membrane technology that features airtight and leakage-proof connections during the fluid transfer process. Transfer is performed through the connection of an I.V. set with an indwelling needle of the ProSeal Injector (or Injector Plus) connector, e.g. the ProSeal Closed System Administration Set (cleared K230343), into the human veins. | The infusion bag is connected with the bag access and, in order to create a fluid path connection between the infusion bag and the bag access, they are connected with the matching end of the ProSeal Injector or Injector Plus (K240171). All system components are sealed with self-resealing membranes incorporating elastomeric double membrane technology that features airtight and leakage-proof connections during the fluid transfer process. Transfer is performed through the connection of an I.V. set with an indwelling needle of the ProSeal Injector (or Injector Plus) connector. The spiking port of the ProSeal™ Bag Spike with Additive Port (or and Seal Tab (suffixed ST model)) is compatible with generic I.V. spikes connected to I.V. Administration Sets for dispensing into the human veins. | Different see Comment #1 |
| Number of access points | Device has 2 access points: 1. Closed system port (injection site) 2. Spike port, I.V. (bag spike (integrated with injection site MLL)) | Device has 3 access points: 1. Closed system port (injection site) 2. Spike port, I.V. (bag spike (integrated with injection site MLL & spiking/administration port)) 3. Spiking port stopper | Different see Comment #1 |

{8}

EPIC

Comparison of intended use characteristics and the technological characteristics

| Characteristic compared | Predicate Device (K241988)
ProSeal™ Closed System Bag Access | Subject Device (K251340)
ProSeal™ Bag Spike with Additive Port | Comment/
Discussion |
| --- | --- | --- | --- |
| Composition of fluid path materials | • Polyisoprene (IR) (membrane of injection site)
• Polypropylene (PP) (spike port, I.V.) | • Polyisoprene (IR) (membrane of injection site)
• Polypropylene (PP) (spike port, I.V.)
• Thermoplastic elastomer (TPE)
(spiking port stopper) | Different
see Comment #2 |
| Connection between component devices within the CSTD system | Collet-style fitting with elastomeric double membranes | Collet-style fitting with elastomeric double membranes | Same |
| Transfer mechanism (role: to facilitate airtight & leak-proof connections to prevent microbial contamination) | Elastomeric double membrane | Elastomeric double membrane | Same |
| Biocompatibility | Acceptable biological risks established | Acceptable biological risks established | Same
see Comments #2 |
| Sterile barrier packaging | Medical grade paper and medical plastic film, heat sealed | Medical grade paper and medical plastic film, heat sealed | Same |
| Sterilization process | Ethylene Oxide (EO), SAL 10^{-6} | Ethylene Oxide (EO), SAL 10^{-6} | Same |
| Shelf-life validation | 3 years (36 months) | 3 years (36 months) | Same |
| Reuse or single-use | Single use only | Single use only | Same |
| Labeling specifications | Met the requirements specified in 21 CFR 801 | Met the requirements specified in 21 CFR 801 | Same |

Submitter's Comments

Comment #1

Subject devices are different from the Predicate device in having a third access point – the spiking port (with its TPE stopper) for connection to standard I.V. spikes of I.V. Administration Sets. The differences between the Subject devices and Predicate device did not raise different questions of safety and effectiveness as functional and analytical testing have been conducted and data evaluated. These data are summarized in section VII.A, and section VII.B of this 510(k) Summary, and in Comment #2 hereunder. The differences were determined to be insignificant as performance results were determined to have met the intended use

Comment #2

Subject device's spiking port stopper is same subcomponent part (made of the same material and of the same configuration) used in the cleared K223674 eZSURE™ Empty Fluid Container's spiking port stopper

Page 5 of 7

{9}

EPIC

## VII. Performance Data Supporting Substantial Equivalence

### A. Functional Performance

The Subject device in this Summary was evaluated to be in conformance with the following ISO standards document:

- ANSI AAMI CN27:2021, General requirements for Luer activated valves (LAVs) incorporated into medical devices for intravascular applications
- ISO 8536-4: 2019, Infusion equipment for medical use - Part 4: Infusion sets for single use, gravity feed
- ISO 15747: 2018, Plastic containers for intravenous injections
- ISO 22413:2010, Transfer sets for pharmaceutical preparations — Requirements and test methods
- ISO 80369-7: 2016, Small-bore connectors for liquids and gases in healthcare application - Part 7, Connectors for intravascular or hypodermic applications
- Intravascular-Administration-Sets-Premarket-Notification-Submissions-[510(k)]---Guidance-for-Industry-and-FDA-Staff

Bench performance verifications and validations performed on the Subject device and referred-to from existing devices (K222929 (data of isoprene membrane in cleared Injection Site w/Extended MLL (K240433), the same membrane part used in Predicate K241988) and K223674):

- Leak integrity test (functional) – per ISO 8536-4:2019, paragraph 7.2 and Annex A.3, performed on Subject device
- Tensile strength test (functional) – per ISO 8536-4:2019, paragraph 7.3 and Annex A.4, performed on Subject device
- Flow rate test (functional) – per ISO 8536-4:2019, Annex A.5.1 performed on Subject device
- Protective caps test (functional) – per ISO 8536-4:2019, Section 7.13, performed on Subject device
- IV Bag Spike penetration force test (functional) – per ISO 22413:2021, Annex A.7 on Subject device
- Spiking port penetration ability (functional) on device cleared under K223674
- Spiking port adhesion strength (functional) on device cleared under K223674
- Impermeability to microorganism (Annex C.2 ISO 15747:2018)(functional) on device cleared under K223674
- Vapor containment test per NIOSH CSTD 2016 draft test protocol (functional) from testing data on device cleared under K222929
- Microbial ingress test per FDA guidance and ANSI AAMI CN27:2021 (functional – 7-days) from testing data on devices cleared under K222929 and K223674

### B. Biocompatibility

In accordance with ISO 10993-1:2018, the Subject device is classified as: Externally Communicating Device, Blood Path Indirect, Prolonged Contact (>24hr to 30d). The following testing were conducted on the existing 510(k) cleared referred-to devices (K222929 (data of isoprene membrane in cleared Injection Site w/Extended MLL (K240433)), K223674 (data of polypropylene 2-port sub-assembly for IV bag, as well as for TPE spiking port stopper) and Predicate K241988):

- Cytotoxicity to ISO 10993-5 performed on devices cleared under K222929 and K223674
- Sensitization to ISO 10993-10 performed on devices cleared under K222929 and K223674
- Intracutaneous reactivity to ISO 10993-10 performed on devices cleared under K222929 and K223674
- Acute systemic toxicity to ISO 10993-11 performed on devices cleared under K222929 and K223674

Page 6 of 7

{10}

EPIC

- 14-day subacute/subchronic systemic toxicity to ISO 10993-11 performed on devices cleared under K222929 and K223674
- In-vitro hemolysis assessment to ISO 10993-4 performed on device cleared under K222929 and K223674
- Material mediated pyrogenicity to ISO 10993-11 performed on devices cleared under K222929 and K223674
- Chemical characterization and toxicological risk management to ISO 10993-18 and ISO 10993-17 on device cleared under Predicate K241988 (leveraging data of polypropylene spike port, I.V. as well as for isoprene membrane)
- Chemical requirements testing to ISO15747:2018, Annex B – Chemical requirements performed on device cleared under K223674
- Particulate matter analysis to ISO 8536-4:2019, Infusion equipment for medical use - Part 4: Infusion sets for single use, gravity feed and USP <788> Particulate Matter in Injections were conducted on devices cleared under K223674 Predicate K241988

## C. Sterility, Shipping, and Shelf-Life

The Subject device complies with sterilization requirements of ISO 11135:2014, Sterilization of Health Care Products – Ethylene Oxide – Part 1: Requirements for Development, Validation and Routine Control of a Sterilization Process for Medical Devices and the following testing/evaluations:

- Simulated shipping testing per ASTM D 4169-16, Standard Practice for Performance Testing of Shipping Containers and Systems (leveraging data under K151650)
- Package integrity tests per ASTM F1980-21, Standard guide for accelerated aging of sterile barrier systems for medical devices and Sterile Barrier Packaging Testing performed on the proposed device: Seal strength – ASTM F88/F88M-21, Standard test method for seal strength of flexible barrier materials; Dye Penetration – ASTM F1929-23, Standard test method for detecting seal leaks in porous medical device packaging by dye penetration; EN 868-5:2009, Packaging materials and systems for medical devices which are to be sterilized – Part 5: Heat and self-sealable pouches and reels of paper and plastic film construction – Requirements and test methods on Subject device
- Pyrogen tests per ANSI/AAMI ST72/2019, Bacterial endotoxins – Test methods, routing monitoring, and alternatives to batch testing, USP 42-NF 37 <151>, Pyrogen test (USP rabbit test), USP 42-NF 37 <161>, Medical Devices-Bacterial Endotoxin and Pyrogen Tests, USP 42- NF 37 <85>, Bacterial Endotoxins Test under K151650 and testing will be conducted on every lot
- Shelf-life of 3 years has been validated using the FDA recognized standard, ASTM 1980-21, Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices on Subject device

## VIII. Clinical Tests

Not applicable

## IX. Conclusion

The difference between the Predicate and the Subject device does not raise any new or different questions of safety or effectiveness. The Subject ProSeal™ Bag Spike with Additive Port (K251340) is substantially equivalent to the Predicate, ProSeal™ Close System Bag Access (K241988), with respect to the indications for use, principles of operation and technological characteristics

Page 7 of 7